What does CDKA stand for?

Cyclin Dependent Kinase

This definition appears very rarely and is found in the following Acronym Finder categories:

Science, medicine, engineering, etc.

Other Resources:

<< Previous	Abbreviation Database Surfer		Next >>
Cyclin-Dependent Kinase 2 Cyclin-Dependent Kinase 2-Associated Protein 1 Cyclin-Dependent Kinase 3 Cyclin-Dependent Kinase 4 Cyclin-Dependent Kinase 4 Inhibitor Cyclin-Dependent Kinase 5 Cyclin Dependent Kinase 6 Cyclin-Dependent Kinase 7 (human gene) Cyclin-Dependent Kinase 8 Cyclin Dependent Kinase 9		Chief Dull Knife College (Lame Deer, MT) Center for Diabetic Kidney Disease (Thomas Jefferson Hospital; Philadelphia, PA) Cyclin-Dependent Kinase D1 (genetics) Carolinas District Kiwanis Foundation (Columbia, SC) Central Difference Kalman Filter Cyclin-Dependent Kinase Inhibitor Cyclin-Dependent Kinase Inhibitor Proteins Cyclin-Dependent Kinase Like Cyclin-dependent Kinase-like 3 Cyclin-Dependent Kinase-Like 5 (gene)

Samples in periodicals archive:

The company is currently evaluating seliciclib (CYC202), an orally-available Cyclin Dependent Kinase inhibitor, in Phase II clinical trials for the treatment of non-small cell lung cancer and B-cell hematological malignancies.

United States patent granted to Cyclacel for cyclin dependent kinase ...

CYC202 (R-roscovitine) is a novel cell cycle drug belonging to the Cyclin Dependent Kinase (CDK) inhibitor class.

CYCLACEL REPORTS PROGRESS WITH 2ND GENERATION CDK INHIBITOR

This gene encodes a protein called cyclin dependent kinase 1, or CDK 1.

Physiology or Medicine

Seliciclib, Cyclacel's orally available cyclin dependent kinase (CDK) inhibitor, has shown encouraging anti-cancer activity in several Phase 1 and Phase 2 studies.

Vall d'Hebron University Hospital and Cyclacel to Initiate Phase 1 ...

In April at the Annual Meeting of the American Association for Cancer Research Cyclacel reported preclinical results from a combination study of seliciclib, an orally-available cyclin dependent kinase (CDK) inhibitor, with epidermal growth factor receptor (EGFR) inhibitor drugs, including erlotinib (Tarceva[R]).

Cyclacel Pharmaceuticals Reports Second Quarter 2007 Financial ...

Seliciclib is an orally available cyclin dependent kinase (CDK) inhibitor that selectively inhibits multiple enzyme targets that are central to the process of cell division and cell cycle control.

Cyclacel Pharmaceuticals Reports First Quarter 2007 Financial Results ...

Nasdaq: CYCC) (Nasdaq: CYCCP) announced today preclinical results from a combination study of seliciclib, an orally-available cyclin dependent kinase (CDK) inhibitor, with epidermal growth factor receptor (EGFR) inhibitor erlotinib (Tarceva[R]).

Cyclacel Pharmaceuticals Reports Preclinical Seliciclib-Erlotinib ...

Seliciclib is the most advanced orally-available, cyclin dependent kinase (CDK) inhibitor in Phase II clinical development in patients with non-small cell lung cancer.

Cyclacel Pharmaceuticals to Present Preclinical Data on Sapacitabine ...